Abstract
Use of Levosimendan in Patients With Low Left Ventricular Ejection Fraction in Ordu/Turkey: Report of Experience with Mini Review
Highlights
In patients undergoing cardiac surgery, postoperative low cardiac output syndrome (LCOS) has been shown to correlate with increased rates of organ failure and mortality
We reported early results of 32 patients (26 male and 6 female; mean age 61.630 ± 9.653 years) who received preoperative levosimendan who underwent coronary artery bypass grafting (CABG) with left ventricular ejection fraction (LVEF) of 35% or less between March 2014 and August 2016
We suggest that levosimendan may be useful in high-risk CABG patients
Summary
In patients undergoing cardiac surgery, postoperative low cardiac output syndrome (LCOS) has been shown to correlate with increased rates of organ failure and mortality. The main risk factor for LCOS is preoperative reduced left ventricular function [1]. For many years catecholamines have been the standard therapy, they carry substantial risk for adverse cardiac and systemic effects, and mortality. Inotropic support is frequently initiated in the perioperative period to improve post-bypass ventricular function. By increasing myocardial oxygen consumption they can cause cardiac ischaemia, with subsequent damage to hibernating but viable myocardium, and arrhythmias. The use of perioperative and postoperative inotropes has been found to be associated with increased mortality and major postoperative morbidity [2]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
